FISH OILS AS CARDIOVASCULAR AGENTS

自20世纪70年代以来的医学文献研究表明，S强烈建议 二十碳五烯酸(EPA)是血栓烷的重要调节剂 和前列腺素活性，主要是其作为“3”的前驱作用。 血栓素类和前列腺素类。最近20年了 流行病学研究发现，鱼类数量增加与 荷兰人的消费与心血管疾病死亡率的降低 人口。一种每天含有超过400毫克EPA的饮食给 相比，心血管疾病死亡率降低了50%以上 饮食中不含鱼油。从这一点来看，这似乎是可能的 其他研究表明，相对较低的EPA富含油类摄入量对慢性 在此基础上，可以大大降低心血管死亡的风险。 PGE技术公司最近将一种鱼油加工成含有30%EPA的不含EPA的 重金属或印刷电路板污染。批准这一计划的主要障碍是 石油作为一种药物，对氧化是不稳定的。第一阶段研究 将专注于使用生育酚和一种新的类别来稳定富含EPA的油 在半合成磷脂中，Lipid X表面活性剂。这些 表面活性剂的独特之处在于它能与油完全相容，因此也是如此 使生育酚溶解。如果能提高抗氧化性 对于超过8小时的ACM，第二阶段研究将包括 动物口服脂类X的毒理学研究 获得FDA批准Lipid X作为食品添加剂。

Studies in the medical literature since the 1970's have strongly suggested that eicosapentaenoic acid (EPA) is a significant modulator of thromboxane and prostaglandin activity, primarily in its role as a precursor of the "3" class of thromboxanes and prostaglandins. Recently a 20-year epidemiological study uncovered a strong correlation between increased fish consumption and decreased cardiovascular disease mortality in a Dutch population. A diet containing greater than 400 mg per day of EPA gave greater than a 50% reduction in cardiovascular disease mortatlity, compared with a diet containing no fish oil. It appears possible from this and other studies that relatively low intake of EPA-rich oils on a chronic basis may substantially reduce the risk of cardiovascular mortality. PGE Technology has recently processed a fish oil to contain 30% EPA without heavy metal or PCB contamination. The major obstacle to approval of this oil as a pharmaceutical is its instability to oxidation. Phase I research will focus on stabilizing EPA-rich oils using tocopherols and a new class of semi-synthetic phospholipids, the Lipid X surfactants. These surfactants are unique in being completely miscible with oils, and so will solubilize the tocopherols. If the resistance to oxidation can be raised to greater than an ACM of 8 hours, Phase II studies would include toxicology studies of Lipid X administered orally to animals, with a goal of obtaining FDA approval of Lipid X as a food additive.